Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis: controlled study
about
Interventions for American cutaneous and mucocutaneous leishmaniasisTreatment of New World cutaneous leishmaniasis with miltefosineMiltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasisClinical status of agents being developed for leishmaniasisIs paromomycin an effective and safe treatment against cutaneous leishmaniasis? A meta-analysis of 14 randomized controlled trials.A controlled, randomized-blinded clinical trial to assess the efficacy of a nitric oxide releasing patch in the treatment of cutaneous leishmaniasis by Leishmania (V.) panamensisTriphenylmethane derivatives have high in vitro and in vivo activity against the main causative agents of cutaneous leishmaniasis.Interventions for American cutaneous and mucocutaneous leishmaniasis: a systematic review update.Paromomycin.Double blind, randomized controlled trial, to evaluate the effectiveness of a controlled nitric oxide releasing patch versus meglumine antimoniate in the treatment of cutaneous leishmaniasis [NCT00317629]An update on pharmacotherapy for leishmaniasisDelivery strategies for antiparasitics.Efficacy of thermotherapy to treat cutaneous leishmaniasis: a meta-analysis of controlled clinical trials.Miltefosine: oral treatment of leishmaniasis.Randomized, double-blinded, phase 2 trial of WR 279,396 (paromomycin and gentamicin) for cutaneous leishmaniasis in Panama.Drug delivery systems for the topical treatment of cutaneous leishmaniasis.Local or systemic treatment for New World cutaneous leishmaniasis? Re-evaluating the evidence for the risk of mucosal leishmaniasis.Therapeutic options for old world cutaneous leishmaniasis and new world cutaneous and mucocutaneous leishmaniasis.LeishMan recommendations for treatment of cutaneous and mucosal leishmaniasis in travelers, 2014.Chemotherapy of leishmaniasis: present challenges.Clinical and parasite species risk factors for pentavalent antimonial treatment failure in cutaneous leishmaniasis in Peru.Intralesional antimony for single lesions of bolivian cutaneous leishmaniasis.Combined suboptimal schedules of topical paromomycin, meglumine antimoniate and miltefosine to treat experimental infection caused by Leishmania (Viannia) braziliensis.Development, characterization, and in vitro biological performance of fluconazole-loaded microemulsions for the topical treatment of cutaneous leishmaniasisStudy of in vitro drug release and percutaneous absorption of fluconazole from topical dosage forms.In vitro skin permeation and retention of paromomycin from liposomes for topical treatment of the cutaneous leishmaniasis.Topical delivery and in vivo antileishmanial activity of paromomycin-loaded liposomes for treatment of cutaneous leishmaniasis.[Effect of a hydrophilic formulation of topical paromomycin on cutaneous leishmaniasis among patients with contraindications for treatment with pentavalent antimonials].In Vitro Sensitivity of Cutaneous Leishmania Promastigote Isolates Circulating in French Guiana to a Set of Drugs.Topical treatment with hexadecylphosphocholine (Miltex) efficiently reduces parasite burden in experimental cutaneous leishmaniasis.
P2860
Q24241646-B8091F42-8D5E-421C-8311-9C13967454D9Q28259788-217F70CC-60E9-4B14-A02E-E87EB5280393Q28271849-0A6D0071-B4BF-41E3-B3B3-FFB455C1B19CQ28279390-269A4F3D-80AB-40C5-BC2F-F4D2F2E586B2Q33409844-2379BD7C-9485-486D-9602-6B9A04ADA44FQ34030245-9124EE85-95A2-474C-A413-D3E415BEE596Q34558182-DD5544B0-B13A-401F-8C93-6587EB6D2EE0Q34700686-FA6AB688-0BF1-41E7-8DCB-68B5783F60A7Q34864208-0CF6BC0A-5194-47D2-9049-BE8EF8F02819Q34883404-4FD2CFDF-E186-44D2-AC4C-318285C12DD2Q34945204-D1FBA887-EF7F-4A32-9380-790E3A41F50BQ35056056-C96CBB2C-9293-4204-8EA6-BD1A3DF3D32FQ35640976-59652DFE-42DF-4B7B-A6B6-2F3D944A624CQ36441483-A54ECC15-E218-4B94-BA4B-62CC42E51E35Q37166175-67D7805A-89CA-4CCC-B9D5-3959F0BC9909Q38020882-7A3C5A56-9683-442A-8B0B-82595F4DD01DQ38136837-793E6BAE-0F7E-4F62-97AB-B6788D083215Q38156421-93322E83-D63B-4069-96C1-0DCFEC5DCF58Q38205451-44C11487-8FD1-4168-9559-76C76758D2A6Q39011875-85B03DA2-CF06-4D3E-9E8E-F179E3F8C722Q39185984-13271153-01F4-47DD-B032-B33B14BCC171Q39471229-EF4AAE19-FF79-4DB4-943D-87A6BA3E205FQ41011525-57B22E1D-4109-44AE-8A9F-95C924E4FA92Q42261151-57CF2589-9DE2-4743-9197-9E71797FE348Q42734594-D7FB0960-D02B-49DF-884A-64D7A02307CCQ44860996-9C02AFFD-5362-495D-918E-51AC9D3FBFBAQ45967362-6CE71F1E-3F3A-47E5-8C7C-8AAF0E522FD3Q46246714-5B845515-4AB4-4C92-B7C2-EF18BCE82072Q53522202-0F1F5A4D-3894-4939-9B3A-C1BA5288DAE7Q54078512-2BDBC346-9112-4DC9-AFF5-FBCB914CDE87
P2860
Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis: controlled study
description
1998 nî lūn-bûn
@nan
1998 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Topical paromomycin/methylbenz ...... eishmaniasis: controlled study
@ast
Topical paromomycin/methylbenz ...... eishmaniasis: controlled study
@en
Topical paromomycin/methylbenz ...... eishmaniasis: controlled study
@nl
type
label
Topical paromomycin/methylbenz ...... eishmaniasis: controlled study
@ast
Topical paromomycin/methylbenz ...... eishmaniasis: controlled study
@en
Topical paromomycin/methylbenz ...... eishmaniasis: controlled study
@nl
prefLabel
Topical paromomycin/methylbenz ...... eishmaniasis: controlled study
@ast
Topical paromomycin/methylbenz ...... eishmaniasis: controlled study
@en
Topical paromomycin/methylbenz ...... eishmaniasis: controlled study
@nl
P2093
P356
P1476
Topical paromomycin/methylbenz ...... eishmaniasis: controlled study
@en
P2093
P356
10.1086/516267
P407
P577
1998-01-01T00:00:00Z